ARTV Stock News & Catalysts – Artiva Biotherapeutics

FEATURED

Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®

Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trialUpdated deep B cell depletion and clinical response data is consistent with previously reported findings; however,

Summary

Oct 27, 2026, 7:30 AM ·Globe Newswire

RECENT

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc)

Oct 2, 2026, 9:05 AM ·Globe Newswire

Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)

Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding,

Oct 1, 2026, 7:30 AM ·Globe Newswire

Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease

SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for

Sep 23, 2026, 7:30 AM ·Globe Newswire

Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for

Sep 17, 2026, 8:00 AM ·Globe Newswire

Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026

Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2a basket trial,

Sep 8, 2026, 7:30 AM ·Globe Newswire

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for

Sep 2, 2026, 8:30 AM ·Globe Newswire

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient

Aug 6, 2026, 4:05 PM ·Globe Newswire

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients

Jul 17, 2026, 7:30 AM ·Globe Newswire

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients

Jun 23, 2026, 4:05 PM ·Globe Newswire

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosisLate-breaking oral

Jun 8, 2026, 6:30 AM ·Globe Newswire

The $13 Million Company Teaching the Immune System to Hunt Cancer

Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For

May 29, 2026, 9:00 AM ·PRNewswire

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with

May 28, 2026, 8:00 AM ·Globe Newswire

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory

May 19, 2026, 4:05 PM ·Globe Newswire

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from

May 19, 2026, 8:00 AM ·Globe Newswire

Artiva Biotherapeutics, Inc. ARTV · News